Recurrent Low-Energy Femoral Shaft Fractures and Osteonecrosis of the Jaw in a Case of Multiple Myeloma Treated With Bisphosphonates

Journal of Oral and Maxillofacial Surgery

Volumn 67, Issue 3, 2009, Pages 645-649

  Grasko, Jonathan M ^a   Herrmann, Richard P ^b   Vasikaran, Samuel D ^b  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IDARUBICIN; MELPHALAN; PAMIDRONIC ACID; PREDNISOLONE; THALIDOMIDE; ZOLEDRONIC ACID;

ADD ON THERAPY; ADULT; ARTICLE; BONE DENSITY; CASE REPORT; DENTAL SURGERY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR SHAFT FRACTURE; FRACTURE FIXATION; HUMAN; JAW OSTEONECROSIS; MALE; MULTIPLE MYELOMA; OSTEOSYNTHESIS; PERIPHERAL NEUROPATHY; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT;

BONE DENSITY CONSERVATION AGENTS; CROSS INFECTION; DIPHOSPHONATES; ESCHERICHIA COLI INFECTIONS; FATAL OUTCOME; FEMORAL FRACTURES; FRACTURES, SPONTANEOUS; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; MAXILLARY DISEASES; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; OSTEOPETROSIS; RECURRENCE;

EID: 60549086159     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2008.11.005     Document Type: Article

References (43)

1. Bataille R. Management of myeloma with bisphosphonates. N Engl J Med 334 (1996) 529
2. Mariette X., Bergot C., Ravaud P., et al. Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. Cancer 76 (1995) 1559
3. Mariette X., Khalifa P., Ravaud P., et al. Bone densitometry in patients with multiple myeloma. Am J Med 93 (1992) 595
4. Miralles G.D., O'Fallon J.R., and Talley N.J. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med 27 (1993) 1919
5. Lacy M.Q., Gertz M.A., Hanson C.A., et al. Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). Am J Hematol 56 (1997) 288
6. Mulleman D., Gaxatte C., Guillerm G., et al. Multiple myeloma presenting with widespread osteosclerotic lesions. Joint Bone Spine 71 (2004) 79
7. Kelly Jr. J.J., Kyle R.A., Miles J.M., et al. Osteosclerotic myeloma and peripheral neuropathy. Neurology 33 (1983) 202
8. Swanson K.M., and Hohl R.J. Anti-cancer therapy: Targeting the mevalonate pathway. Curr Cancer Drug Targets 6 (2006) 15
9. Tanaka Y., Abe M., Hiasa M., et al. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13 (2007) 816
10. Diamond T., Levy S., Day P., et al. Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity. Br J Haematol 97 (1997) 641
11. Weinstein R.S., Jilka R.L., Parfitt A.M., et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102 (1998) 274
12. Gohel A., McCarthy M.B., and Gronowicz G. Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology 140 (1999) 5339
13. Canalis E. Clinical review 83: mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 81 (1996) 3441
14. Rodino M.A., and Shane E. Osteoporosis after organ transplantation. Am J Med 104 (1998) 459
15. Shultz T.D., Bollman S., and Kumar R. Decreased intestinal calcium absorption in vivo and normal brush border membrane vesicle calcium uptake in cortisol-treated chickens: Evidence for dissociation of calcium absorption from brush border vesicle uptake. Proc Natl Acad Sci USA 79 (1982) 3542
16. MacAdams M.R., White R.H., and Chipps B.E. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 104 (1986) 648
17. Fitzgerald R.C., Skingle S.J., and Crisp A.J. Testosterone concentrations in men on chronic glucocorticosteroid therapy. J R Coll Physicians Lond 31 (1997) 168
18. Schwartz Z., Nasatzky E., Ornoy A., et al. Gender-specific, maturation-dependent effects of testosterone on chondrocytes in culture. Endocrinology 134 (1994) 1640
19. Pfeilschifter J., and Diel I.J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18 (2000) 1570
20. Dispenzieri A., Kyle R.A., Lacy M.Q., et al. POEMS syndrome: Definitions and long-term outcome. Blood 101 (2003) 2496
21. Takatsuki K., and Sanada I. Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases. Jpn J Clin Oncol 13 (1983) 543
22. Driedger H., and Pruzanski W. Plasma cell neoplasia with peripheral polyneuropathy. A study of five cases and a review of the literature. Medicine 59 (1980) 301
23. Whyte M.P., Wenkert D., Clements K.L., et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 349 (2003) 457
24. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567
25. Tolar J., Teitelbaum S.L., and Orchard P.J. Osteopetrosis. N Engl J Med 351 (2004) 2839
26. Sarasquete M.E., Garcia-Sanz R., Marin L., et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis. Blood (2008) Jul 1 [Epub ahead of print]
27. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538
28. Wood J., Bonjean K., Ruetz S., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 (2002) 1055
29. D'Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91 (1994) 4082
30. Brem S.S., Zagzag D., Tsanaclis A.M., et al. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol 137 (1990) 1121
31. Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24 (2006) 945
32. Belch A.R., Bergsagel D.E., Wilson K., et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9 (1991) 1397
33. Green J.R. Bisphosphonates: preclinical review. Oncologist 9 Suppl 4 (2004) 3
34. Giraudo E., Inoue M., and Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114 (2004) 623
35. Croucher P.I., De Hendrik R., Perry M.J., et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18 (2003) 482
36. Kyle R.A., Yee G.C., Somerfield M.R., et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25 (2007) 2464
37. Hoff A.O., Toth B.B., Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23 (2008) 826
38. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479
39. Khan A.A., Sandor G.K., Dore E., et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35 (2008) 1391
40. Lenart B.A., Lorich D.G., and Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358 (2008) 1304
41. Kwek E.B., Goh S.K., Koh J.S., et al. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?. Injury 39 (2008) 224
42. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (2005) 1294
43. Melton III L.J., Kyle R.A., Achenbach S.J., et al. Fracture risk with multiple myeloma: A population-based sudy. J Bone Miner Res 20 (2005) 487